Sitagliptin Might Be a Favorable Antiobesity Drug For New Onset Diabetes After a Renal Transplant

Abstract

In a group of renal transplant recipients with new-onset diabetes mellitus after a transplant in whom glycemia was not controlled adequately by oral hypoglycemic agents, the addition of sitagliptin helped to achieve glycemic control similar to insulin glargine but with a marginal weight advantage.